8-K filed Sep 2, 2026 at 07:06 ET
uniQure announced submission of a Biologics License Application (BLA) to the FDA seeking accelerated approval of its gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, along with a parallel Marketing Authorisation Application (MAA) to the UK MHRA. The submissions are supported by three-year Phase I/II data showing slowed disease progression, and the company has requested priority review, which could shorten the FDA review cycle to six months. This is a major regulatory milestone for a first-in-class therapy addressing a large unmet need, though approval is not guaranteed and the stock has historically underperformed on high-impact events.